Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide for liver volume reduction in polycystic liver disease
NL-OMON30533Phase 4Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, single-arm trial of lanreotide in Polycystic liver disease (PLD) and autosomal dominant polycystic kidney disease (ADPKD), sponsored by Radboud University Medical Center. Planned start Mar 2007; status: not yet recruiting.
02
Drugs
lanreotide
03
Conditions
Polycystic liver disease (PLD)autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON30533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30533.